Home monitoring in Idiopathic Pulmonary Fibrosis; improving use of anti-fibrotic medication and quality of life

Completed

Conditions: idiopathic pulmonary fibrosis
lung fibrosis
10024967

Registration Number: NL-OMON46643

Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 90

Inclusion Criteria

All patients with a diagnosis of IPF according to the ATS 2011 criteria and HRCT/pathology criteria of the Fleischner Society (White paper November 2017), about to start on anti-fibrotic treatment (either nintedanib or pirfenidone) will be invited to participate.

Exclusion Criteria

not able to speak, read or write in Dutch,
not able to comply with the study protocol according to the judgement of the patient and/or investigator

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary outcome is the difference in the change in total score of K-BILD<br /><br>(Health-related quality of life) between the home monitoring group and the<br /><br>standard care group at 24 weeks.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- Costs and cost-effectiveness<br /><br>- Patient expectations and satisfaction with medication<br /><br>- Patient satisfaction with care process<br /><br>- Number of patients who discontinue use of medication<br /><br>- Amount of contacts with healthcare providers and number of visits per patient<br /><br>- FVC decline at 24 weeks<br /><br>- Personal goal of patient defined at start of study<br /><br>- Home monitoring values compared to in hospital values of lung function.<br /><br>- Relation between FVC measurements and PROMs.<br /><br>- Effect of home monitoring on different parameters of (HR)QOL</p><br>